A potential obesity-related modification of the CD40-CD40L system merits further investigation because the latter is more broadly involved in the regulation of immune responses and there is already interest in developing an agonist anti-CD40 antibody as a promising cancer treatment strategy targeting the apoptosis of CD40-expressing tumours36. This evidence concerns the gene CD40 and cancer.